Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Axsome Therapeutics ( (AXSM) ) is now available.
On August 4, 2025, Axsome Therapeutics reported a significant financial performance for the second quarter of 2025, with a 72% year-over-year increase in net product revenue, reaching $150 million. The company highlighted the successful launch of SYMBRAVO for migraines and the strong sales growth of AUVELITY and SUNOSI. Axsome is progressing with regulatory submissions for AXS-05 and AXS-12, aiming to expand its product pipeline addressing serious psychiatric and neurological conditions. The company also reported a reduced net loss compared to the previous year, indicating improved financial health.
The most recent analyst rating on (AXSM) stock is a Buy with a $190.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.
Spark’s Take on AXSM Stock
According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.
Axsome Therapeutics benefits from robust revenue growth and positive corporate developments, such as new product launches and strategic financing. However, financial instability and regulatory challenges weigh heavily on its overall score.
To see Spark’s full report on AXSM stock, click here.
More about Axsome Therapeutics
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company offers products such as AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for migraines, with a strong emphasis on neuroscience innovations.
Average Trading Volume: 655,150
Technical Sentiment Signal: Buy
Current Market Cap: $5.07B
Learn more about AXSM stock on TipRanks’ Stock Analysis page.